CALQUENCE AstraZeneca Pty Ltd
Product name
CALQUENCE
Sponsor
Accepted date
Jan-2025
Active ingredients
acalabrutinib maleate monohydrate
Proposed indication
CALQUENCE (acalabrutinib) is for the treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma (either as a monotherapy or in combination with other anticancer drugs).
Application type
C (new indication)
Publication date
Jan-2025